The company that built an entire GI-robotics roadmap on one stubbornly simple idea: a tube that can decide to be stiff.
Here is a fact about colonoscopy that nobody puts on a brochure: the scope loops. You push a long, flexible tube into a winding organ, it hits a bend, and instead of advancing it coils up on itself - like feeding a garden hose into a drainpipe and watching it kink. Looping causes pain, failed procedures, and, occasionally, worse. It has been a known problem for as long as there have been flexible scopes, which is to say decades. Mostly, the field has treated it as weather - something you cope with, not something you fix.
Neptune Medical, founded in 2016 by Alex Tilson, decided it was not weather. Its answer is a technology called Dynamic Rigidization, and the elevator version is almost suspiciously simple: build a thin-walled tube out of layered materials, then pull a vacuum on it. Remove the air and the layers lock against each other - the tube snaps rigid. Let the air back in and it goes floppy again. Flexible when you need to steer, rigid when you need to hold a position. A spine, on demand.
That is the whole company, really. Not in the dismissive sense - in the way that the best hardware companies are usually one good idea executed with unusual discipline. Neptune took that single switch and built a product around it, got it cleared by the FDA, put it in more than 15,000 patients, and then used the same physics to build a robot. Which is a more interesting story than "startup raises money," so let's tell it.
Everything Neptune sells depends on this toggle. A conventional scope is stuck being flexible; that's what lets it navigate, but it's also why it loops. Neptune's insight was that flexibility and rigidity don't have to be a permanent choice. They can be a setting.
Air in. The overtube bends freely to navigate every twist of the colon.
Air out. Layers lock. The tube holds its shape and stops the scope from looping.
The core technology: vacuum-activated layers that toggle thin-walled tubes - overtubes, catheters, cannulae - between flexible and rigid states, as often as a procedure demands. Everything else is downstream of this.
An overtube that rides over an existing endoscope, managing loop formation and helping the operator control the scope tip. Neptune's first commercial device and, notably, used in over 15,000 patients at leading U.S. hospitals.
A robotic endoscopy system for colon navigation built on the same platform. Not yet for sale - but its first-in-human study posted 100% cecal intubation and zero adverse events across 50 patients.
In May 2026, Neptune presented results from CARE 1 - the first-in-human study of Triton - at Digestive Disease Week. In an industry that celebrates incremental gains, the headline was that nothing went wrong. That is harder to achieve than it sounds.
For a gastroenterologist, the pitch is direct: reach the target more reliably, with less fighting against loops, and - per the Triton data - considerably less physical strain on your own body. That last part is easy to overlook. The endoscopist's shoulders, wrists, and back are a real bottleneck in a screening system that needs to scale. A device that reports 67% lower operator burden isn't just kinder to the doctor; it's a lever on how many procedures can get done.
For a hospital, Pathfinder is a single-use device that slots into existing endoscopy workflows and rides over scopes clinicians already own - so the incumbent equipment gets better without being replaced. For a patient, the promise is the quiet kind: fewer failed procedures, less pain, a better chance the scope actually reaches where it needs to go.
Alex Tilson starts the company in Silicon Valley to build devices around Dynamic Rigidization.
The rigidizing overtube becomes the first commercial device to attack looping in GI procedures.
Adoption spreads across leading U.S. hospitals and academic centers, into the thousands of patients.
Neptune raises a Series D with Olympus and Sonder Capital - and spins out Jupiter Endovascular to focus on GI robotics.
The robotic system posts 100% cecal intubation and no adverse events, presented at DDW 2026.
In August 2024, Neptune closed a $97M Series D led by Sonder Capital, with participation from Olympus Corporation of the Americas - a global endoscopy incumbent whose money doubles as a strategic signal. Then it did something most companies don't: right after raising, it gave a business away. Jupiter Endovascular was spun out as an independent company so Neptune could go all-in on gastroenterology robotics. Focus isn't what you add; it's what you're willing to let go of.
"Dynamic Rigidization instantly toggles thin-walled tubes between flexible and rigid states to manage looping during a procedure."
The most telling detail in Neptune's cap table isn't a dollar figure - it's a name. The board chairman is Fred Moll, a founder of Intuitive Surgical, the company behind the da Vinci robot that more or less defined surgical robotics. When the person who built the future once bets on your GI robot, that's less a testimonial and more a tell. Add a strategic check from Olympus, and Neptune has surrounded a hard physics problem with people who've navigated the medtech gauntlet before.
The logo is a ringed blue planet - a nod to Neptune - and the animated version echoes the flex-to-rigid motion of the tech itself.
The core mechanism is essentially vacuum-powered: pull air out of layered walls and a floppy tube snaps rigid.
Pathfinder doesn't replace the colonoscope - it rides over it, giving an existing scope a spine on demand.
Triton's first-in-human study ran at a single center in Poland, following patients for 14 days post-procedure.